S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VERA

Vera Therapeutics (VERA) Stock Price, News & Analysis

$43.12
-0.71 (-1.62%)
(As of 03/28/2024 ET)
Today's Range
$42.38
$44.44
50-Day Range
$14.93
$49.14
52-Week Range
$5.95
$50.78
Volume
666,497 shs
Average Volume
1.29 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.29

Vera Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.1% Downside
$32.29 Price Target
Short Interest
Bearish
16.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Vera Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$36.25 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.21) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

780th out of 938 stocks

Pharmaceutical Preparations Industry

345th out of 417 stocks

VERA stock logo

About Vera Therapeutics Stock (NASDAQ:VERA)

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

VERA Stock Price History

VERA Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $34.00
Vera Therapeutics: Q4 Earnings Insights
VERA Mar 2024 17.500 call
VERA Apr 2024 40.000 call
VERA Apr 2024 50.000 put
Vera Therapeutics Inc Class A VERA
RWE CEO: no plans for big, transformative deals
Are foot peels safe? Derms weigh in
See More Headlines
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VERA
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.29
High Stock Price Target
$56.00
Low Stock Price Target
$22.00
Potential Upside/Downside
-25.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-95,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.77 per share

Miscellaneous

Free Float
40,633,000
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.10
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Marshall Fordyce M.D.Dr. Marshall Fordyce M.D. (Age 49)
    Founder, President, CEO & Director
    Comp: $828.89k
  • Mr. Sean P. Grant M.B.A. (Age 39)
    Chief Financial Officer
    Comp: $585.5k
  • Mr. Joseph R. Young M.B.A. (Age 51)
    Senior VP of Finance & Chief Accounting Officer
  • Mr. Julien E. Capers J.D.
    VP & Head of Legal
  • Ms. Kelly Rauber
    VP & Head of Human Resources
  • Mr. Tom Doan (Age 52)
    Senior Vice President of Development Operations
  • Ms. Lauren Frenz (Age 39)
    Chief Business Officer
  • Dr. Neeraj Pakala M.B.A.
    Ph.D., Senior VP and Head of Product Development & Manufacturing
  • Dr. Kerry Cooper M.D.
    Senior Vice President of Medical Affairs
  • Dr. Robert M. Brenner M.D. (Age 56)
    Chief Medical Officer

VERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VERA shares.
View VERA analyst ratings
or view top-rated stocks.

What is Vera Therapeutics' stock price target for 2024?

8 analysts have issued 1 year price targets for Vera Therapeutics' stock. Their VERA share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $32.29 in the next year. This suggests that the stock has a possible downside of 25.1%.
View analysts price targets for VERA
or view top-rated stocks among Wall Street analysts.

How have VERA shares performed in 2024?

Vera Therapeutics' stock was trading at $15.38 at the start of the year. Since then, VERA stock has increased by 180.4% and is now trading at $43.12.
View the best growth stocks for 2024 here
.

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERA earnings forecast
.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.33.

What ETF holds Vera Therapeutics' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 98,152 shares of VERA stock, representing 1.01% of its portfolio.

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are Vera Therapeutics' major shareholders?

Vera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (6.95%), Vanguard Group Inc. (3.11%), Vanguard Group Inc. (3.11%), Schroder Investment Management Group (2.12%), Point72 Asset Management L.P. (1.88%) and Goldman Sachs Group Inc. (1.24%). Insiders that own company stock include Beth C Seidenberg, Carlyle Group Inc, Celia Lin, Commodore Capital Lp, Joanne Curley, Llp Abingworth, Maha Katabi, Marshall Fordyce, Patrick G Enright, Sean Grant and Sofinnova Venture Partners X,.
View institutional ownership trends
.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners